Convalescent plasma for preventing critical illness in COVID-19: A phase 2 trial and immune profile

RationaleThe COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an unprecedented event requiring rapid adaptation to changing clinical circumstances. Convalescent immune plasma (CIP) is a promising treatment that can be mobilized rapidly in a pandemic setting. ObjectivesWe tested whether administration of SARS-CoV-2 CIP at hospital admission... Show more